NASDAQ · BVS

Bioventus Inc.

$12.45 +$0.65 (+5.51%) 1D After hours

Key Metrics

$799.43M
Market cap
28.07×
P/E · TTM
$576.30M
Revenue · TTM
$28.48M
Net income
EPS · TTM $0.43
Dividend yield
Free cash flow $100.63M
Beta · 1Y 0.85
EBITDA · TTM $79.99M
Gross margin 68.7%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jul 6
    The stock moved +12.4% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jul 6
  • Jun 1
    From its May 20 high, the share price fell 28%.

    Peak close $10.94 on May 20; trough close $7.93 on Jun 1. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -28%
  • May 21
    The stock moved -13.2% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 21

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$799.43M
Enterprise value$1.03B
Shares outstanding67.7M
52-wk range$5.81 – $12.53
Avg volume · 20D396.3K
Net cash −$234.13M
Book value / share$2.86
IndustrySurgical & Medical Instruments & Apparatus
ExchangeNASDAQ
About Bioventus Inc.
IPO dateFeb 11, 2021
Employees940

Bioventus Inc is a medical device company focused on developing and commercializing products to relieve pain and address musculoskeletal conditions. The company operates through two reporting segments, U.S.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E28.07
P/S1.39
P/FCF7.94
EV/EBITDA12.92
EV/Sales1.79
Graham №$5.27

Profitability

Gross 68.7%
Operating 5.8%
Net 4.9%
FCF 17.5%
ROE / ROIC 16.9% · 8.1%

Financial Health

Current ratio1.69
Quick ratio1.13
Debt / equity1.44
Debt / EBITDA 3.40
Net cash −$234.13M
Working capital$101.72M

Cash Flow · TTM

Operating CF $102.94M
Capex −$2.31M
Free cash flow $100.63M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

8 / 9
Strong fundamentals · 8 of 9 signals passing

Altman Z-Score

1.7
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

$5.27 vs $12.45
Trades 2.4× above classic defensive value — priced for growth
Fundamentals through 2026-03-28 · computed by TickerWolf from SEC filings